STRYKER CORP
SYKNYSEMedical Devices • Healthcare
Comprehensive AI Analysis
Strategic AI Analysis for SYK
Checking whether the approved providers contain enough current financial data for a reliable report.
Summary
Source-linked company research for SYK
Factor Scorecard
Mechanical 0-100 composites from the displayed inputs. Bands and colours are numerical aids, not security ratings or investment actions.
Latest results at a glance
Insights from the latest company results and reports · filed 30 Jul 2026
Quarterly Revenue and Earnings Growth
Reported net sales increased 9.4% to $6.6 billion in the second quarter.
Segment Performance
MedSurg and Neurotechnology net sales reached $3.6 billion, up 9.7% year-over-year. Orthopaedics net sales were $3.0 billion, increasing 9.1% in the quarter.
Updated Full-Year Guidance
The company narrowed its full-year 2026 guidance, expecting organic net sales growth between 8.3% and 9.3%. Adjusted net earnings per diluted share are expected in the range of $14.95 to $15.10.
Margin Expansion
Reported gross profit margin was 68.3% and operating income margin was 25.2% in the quarter.
Recent Contract Award
Defense Logistics Agency.
Price Chart
NYSE:SYK via TradingView
Loading TradingView chart...
Overview
Quarterly income statement data isn't available for this company.
No Data
No annual financial data available.
Financial Fundamentals
Growth, quality, valuation, cash generation, and balance-sheet strength.
Growth
TTM revenue plus current, long-term, forward, and accelerating top-line trends.
Earnings
Trailing EPS, current EPS growth, long-term compounding, surprise, and forward expectations.
Profitability
TTM margin and return metrics that reflect pricing power and business quality.
Cash Flow
TTM free cash flow, growth, margin, and operating-cash conversion quality.
Valuation
Metrics ranked by issuer type, financial state, and input quality.
Forward P/E
Forward P/E is the primary lens because positive expected earnings make the next operating period directly assessable.
Financial Health
Latest-quarter liquidity and leverage checks plus TTM interest coverage.
Shareholder Signals
Capital returns and dilution checks sourced from statements and insider filings.
Peer Comparison
| Ticker | Price | Mkt Cap | EV/EBITDA | Fwd P/E | Rev Growth | Gross Margin | FCF Yield |
|---|---|---|---|---|---|---|---|
SYKSTRYKER CORP | $330.69 | $126.8B | 19.3x | 22.0x | +8.5% | 65.0% | 3.7% |
Company Profile
About the Company
Stryker Corporation operates as a medical technology company in the United States and internationally. It operates through two segments, MedSurg and Neurotechnology, and Orthopaedics. The MedSurg and Neurotechnology segment offers surgical equipment, patient and caregiver safety technologies, navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, clinical communication and artificial intelligence-assisted virtual care platform technology, and minimally invasive products for the treatment of acute ischemic and hemorrhagic stroke and venous thromboembolism; traditional brain and open skull based surgical procedures products; and orthobiologic and biosurgery products, including synthetic bone grafts and vertebral augmentation products. The Orthopaedics segment provides implants for use in total joint replacements, such as hip, knee and shoulder, ankle, and trauma and extremities surgeries; and Mako Shoulder, which expands the smart robotics suite of applications. The company sells its products to doctors, hospitals, and other healthcare facilities through company-owned subsidiaries and branches, as well as third-party dealers and distributors in approximately 61 countries. Stryker Corporation was founded in 1941 and is headquartered in Portage, Michigan.
Next Earnings Date
Oct 29, 2026
Loading latest news...